Literature DB >> 18818924

Clinical observations programme in SpA: disease parameters, treatment options and practical management issues.

Dirk Elewaut1, Filip Van den Bosch, Gust Verbruggen, Filip de Keyser, Bert Vander Cruyssen, Herman Mielants.   

Abstract

Spondyloarthritides (SpAs) are a cluster of chronic inflammatory rheumatic diseases that typically involve inflammation of axial and peripheral joint or tendon and ligament insertions, distinct radiographic changes and diverse extra-articular features. Conventional treatments relieve the signs and symptoms but do not prevent disease progression. TNFalpha inhibitors provide clinicians with the potential to treat the underlying pathology and to alter disease progression. By targeting the underlying inflammatory mechanisms, TNFalpha blockade can treat any extra-articular manifestations of SpA.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18818924     DOI: 10.1007/s00296-008-0714-5

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  81 in total

1.  Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis.

Authors:  H Marzo-Ortega; D McGonagle; P O'Connor; P Emery
Journal:  Ann Rheum Dis       Date:  2003-01       Impact factor: 19.103

2.  A comparative study of the usefulness of the Bath Ankylosing Spondylitis Functional Index and the Dougados Functional Index in the assessment of ankylosing spondylitis.

Authors:  A Spoorenberg; D van der Heijde; E de Klerk; M Dougados; K de Vlam; H Mielants; H van der Tempel; S van der Linden
Journal:  J Rheumatol       Date:  1999-04       Impact factor: 4.666

Review 3.  Associations between ankylosing spondylitis, psoriatic arthritis, Reiter's disease, the intestinal arthropathies, and Behcet's syndrome.

Authors:  J M Moll; I Haslock; I F Macrae; V Wright
Journal:  Medicine (Baltimore)       Date:  1974-09       Impact factor: 1.889

Review 4.  Chondroprotective drugs in degenerative joint diseases.

Authors:  G Verbruggen
Journal:  Rheumatology (Oxford)       Date:  2005-11-08       Impact factor: 7.580

5.  Spondyloarthropathy in the community: clinical syndromes and disease manifestations in Alaskan Eskimo populations.

Authors:  G S Boyer; D W Templin; A Bowler; R C Lawrence; S P Heyse; D F Everett; J C Cornoni-Huntley
Journal:  J Rheumatol       Date:  1999-07       Impact factor: 4.666

6.  Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association.

Authors:  K de Vlam; H Mielants; C Cuvelier; F De Keyser; E M Veys; M De Vos
Journal:  J Rheumatol       Date:  2000-12       Impact factor: 4.666

7.  Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.

Authors:  W G Dixon; K Watson; M Lunt; K L Hyrich; A J Silman; D P M Symmons
Journal:  Arthritis Rheum       Date:  2006-08

8.  HLA-B27-associated spondyloarthritis and enthesopathy in childhood: clinical, pathologic, and radiographic observations in 58 patients.

Authors:  J C Jacobs; W E Berdon; A D Johnston
Journal:  J Pediatr       Date:  1982-04       Impact factor: 4.406

9.  Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial.

Authors:  J Peter Kaltwasser; Peter Nash; Dafna Gladman; Cheryl F Rosen; Frank Behrens; Peter Jones; Jürgen Wollenhaupt; Franziska G Falk; Philip Mease
Journal:  Arthritis Rheum       Date:  2004-06

10.  Clinical features of acute anterior uveitis.

Authors:  A Rothova; W G van Veenedaal; A Linssen; E Glasius; A Kijlstra; P T de Jong
Journal:  Am J Ophthalmol       Date:  1987-02-15       Impact factor: 5.258

View more
  1 in total

Review 1.  Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease.

Authors:  Arnd Heiligenhaus; Stephan Thurau; Maren Hennig; Rafael S Grajewski; Gerhild Wildner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-08-25       Impact factor: 3.117

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.